We are thrilled to announce that LISCure Biosciences will be attending the 2025 J.P. Morgan Healthcare Conference in San Francisco. We can’t wait to see what’s in store next week for life sciences innovation, collaboration, and progress. Our CEO HS CHIN, CFO #TaeheeKim, CTO Kyoungsub Song, Ph.D. Song, and CBO Lynn K. will be on the grounds connecting with global industry leaders, innovators, and partners. If you are attending #JPM2025 and want to discuss opportunities to collaborate or learn more about LISCure's innovative therapeutic programs and drug delivery platform, please drop us a message!
LISCure Biosciences Inc.
Biotechnology Research
성남시, 경기도 160 followers
Live Biotherapeutics Immunotherapeutic Drugs
About us
The human microbiome has never been so emphasized. There are some well-known scientific discoveries associated with the human microbiome. i) 95% of bacteria live in the gut, which has a high correlation with metabolic diseases ii) 70% of the immune system is housed in the gut, which has a high correlation with cancer and immune diseases iii) central nervous system is connected to the gut, which has a high correlation with CNS. LISCure is the only company that covers all of its indications based on recent scientific discoveries. LISCure is a clinical-stage biotherapeutic company focused on developing bacteria-mediated immunotherapy using a single strain approach for major therapeutic areas. The company focuses on two therapeutic modalities. 1) Bacteria-mediated Immunotherapy, which is oncology focus injectable therapeutics achieving complete remission with a single dose as monotherapy in our animal models. 2) Microbiome Therapeutics, which is conventional microbiome therapeutics but novel indications such as metabolic diseases, autoimmune diseases, CNS, etc. LISCure has over 10 different drug candidates selected through its own LMT platform technology, which is composed of therapeutic screening, microbial optimization, and microbiome database. There are currently two candidates, LB-P6 and LB-P8, under clinical trial phase 1, and two other candidates, LB-P2D and P4, are expected to enter clinical trial this year. For more information, please visit http://www.liscure.bio/eng/main/ .
- Website
-
https://www.liscure.bio/kr/
External link for LISCure Biosciences Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- 성남시, 경기도
- Type
- Privately Held
- Founded
- 2018
Locations
-
Primary
대왕판교로670
유스페이스2 B동 801GH
성남시, 경기도, KR
-
분당구 대왕판교로 700 코리아바이오파크
성남시, 경기도 13488, KR
-
Boston, MA, 02109, US
Employees at LISCure Biosciences Inc.
Updates
-
2024-10-31 Microbiome-based treatments are expanding into brain and neurological diseases. Domestic pharmaceutical and biotech companies are also increasingly pursuing the development of new drugs using the microbiome. The microbiome has recently emerged as a potential treatment for diseases such as Alzheimer's, Parkinson's, autism, stroke, and depression, referring to the genetic information of microorganisms like bacteria and viruses in the human body. Mainly residing in the gut, the microbiome influences metabolism, digestion, and immune function, earning it the title "the second genome." Initially, microbiome-based therapies were developed for oncology, autoimmune, and infectious diseases, but research has now expanded to include treatments for brain and neurological disorders. Although the gut and brain are physically separate, they communicate through several pathways, with gut-produced neurotransmitters like serotonin and dopamine crossing the blood-brain barrier and affecting the brain. Additionally, immune interactions through the microbiome help influence brain function. Recent studies have shown that changes in the microbiome were observed in patients with Alzheimer's disease and Parkinson's disease at an early stage. In 2019, the U.S. Food and Drug Administration (FDA) recognized fecal microbiota transplantation as a treatment for autism spectrum disorder. Additionally, there are studies indicating that metabolites produced by gut microbiota can alleviate peripheral and central nervous system inflammation, showing potential for stroke treatment. Domestic companies are actively entering the microbiome drug market, as there are only two FDA-approved microbiome therapies to date, creating opportunities for early market positioning. Celltrion signed a joint research and development agreement with domestic microbiome-based drug developer LISCure Biosciences Inc. last year for the development of a microbiome treatment for Parkinson's disease. This collaboration aims to strengthen their pipeline for degenerative neurological disease treatments. Chongkeundang Bio established a microbiome research center in collaboration with Yonsei University Medical Center in 2022 and is focusing on the development of treatments for diseases such as Alzheimer's disease. Genom&Company acquired the U.S. biotech company CytoBio Sciences in 2020 and secured a microbiome treatment for autism, "SB-121." HEMPharma is currently conducting a global Phase 2 clinical trial for its microbiome-based depression drug, "HEMP-001." PeopleBio's subsidiary, PharmacoBio, has received approval for the Phase 1 clinical trial plan (IND) for "DDN-A-0101," a treatment for Alzheimer's disease, from the KFDA Safety. https://lnkd.in/ggzAZCZU
-
✨LISCure Biosciences Inc. At LISCure Bio, we recently tried something new. Traditionally, we provided new employees with a brief orientation about the company, including an introduction to our working methods. This time, however, our CFO from the Business Planning Team, Mr. Kim Tae-hee, personally created the materials and led the meeting. The training covered key topics such as our company's products and vision, a comparative analysis of our competitors, and our domestic and international investment status. The presentation was filled with motivational content that resonated well with the employees.👍 Given Mr. Kim's extensive experience and deep industry knowledge, even those of us who thought we knew a lot gained new insights. It was a significant and informative session. We plan to continue experimenting with various approaches starting with this town hall meeting. By the time we conduct our next round of recruitment, we are considering organizing a 1-night, 2-day experiential workshop for new and junior employees.😁 After the meeting, the CEO treated us to snacks (perhaps as a subtle hint to keep working hard). This time, it was chicken and pizza.🫰🍕🍗 In this hot and humid weather, we had a joyful and happy time laughing and enjoying ourselves with the employees in a cool place.
-
2024-04-01 US FDA grants fast track status to LISCure’s LB-P8 drug for PSC LISCure plans to conduct a Phase II study of investigational drug LB-P8 across multiple sites in the US and Europe. The US Food and Drug Administration (FDA) has granted fast track designation to LISCure Biosciences’ investigational drug LB-P8, for the treatment of primary sclerosing cholangitis (PSC). With the designation, the company will fast track the development of the drug to fulfill the unmet medical needs of people affected by PSC. LB-P8 is designed to treat inflammation and fibrosis as well as to modulate bile acids. LISCure said the LB-P8 live biotherapeutic product (LBP) is the only one of its kind reported to be in clinical development for PSC, a rare and chronic liver disease with no approved treatment options. The drug previously received orphan drug designation for PSC in 2022. https://lnkd.in/g5VjhV-G
-
2023-10-23 DongKook Pharmaceutical and LISCure Bio Announce Development Agreement for Dry Functional Ingredients. DongKook Pharmaceutical announced on the 23rd that it has entered into a business agreement with LISCure Biosciences for the development of functional ingredients for health functional foods. Under the agreement, both companies will jointly develop individualized formulations using strains effective in reducing body fat. The developed functional ingredients are scheduled to be commercialized under DongKook Pharmaceutical's health functional food brand 'My Fit,' which was launched in June. https://lnkd.in/gxbS8Ps9
동국제약, 리스큐어바이오와 건기식 기능성 소재 개발 협약
hankyung.com
-
2023-10-24 LISCure Biosciences, in collaboration with Mayo Clinic researchers, will present oral findings on their primary sclerosing cholangitis (PSC) treatment candidate and clinical plans at the American Association for the Study of Liver Diseases (AASLD 2023) in Boston, USA, from November 10 to 14. LISCure Biosciences liver disease treatment LB-P8, which directly regulates liver fibrosis and inflammation using microbiome-based therapy, received Orphan Drug Designation (ODD) from the FDA last December. A LISCure spokesperson stated, "We plan to finalize our IND and Fast Track designation application to the FDA by the end of this year, and commence Phase 2 clinical trials at 10 sites including Mayo Clinic starting Q1 2024." Since 2021, LISCure has been collaborating with Mayo Clinic, a top global hospital, on developing treatments for liver diseases. The results of this study will be presented by Professor Steven O’Hara of Mayo Clinic's Division of Gastroenterology. AASLD, along with the European Association for the Study of the Liver (EASL), is one of the largest conferences in the field of liver diseases, attended by over 10,000 researchers, global pharmaceutical companies, and others. The LISCure spokesperson added, "At this AASLD meeting, we have scheduled meetings not only with major global pharmaceutical companies but also with numerous new companies and the NIH-affiliated PSC consortium." https://lnkd.in/gbWFuQk5
[약업신문]리스큐어, 美 간 학회서 간 질환 신약후보 연구 결과 구두발표 예정
yakup.com
-
2023-11-03 LISCure BioSciences, a Microbiome Drug Development Company, Joins U.S. BioMarker Consortium LISCure BioSciences, specializing in microbiome-based drug development, announced on the 3rd that it has joined a bioMarker consortium involving U.S. government agencies and global pharmaceutical companies. BioMarkers are indicators using DNA, proteins, metabolites, etc., to assess changes inside the body, predicting cancer progression or treatment responses. According to LISCure BioSciences, this consortium includes U.S. regulatory authorities such as the FDA, NIH, CMS, along with top 10 global pharmaceutical companies, patient advocacy groups, and others. LISCure BioSciences has previously received orphan drug designation from the FDA for a rare medication targeting primary sclerosing cholangitis (PSC), a rare liver disease. https://lnkd.in/gy7bXWh3
신약 개발사 리스큐어, 美 바이오마커 컨소시엄 합류 | 연합뉴스
yna.co.kr
-
2023-10-05 LISCure Biosciences Appoints New CFO, Tae-hee Kim, Former KB Securities Executive LISCure Biosciences announced on the 5th that they have hired Tae-hee Kim, a former bio sector analyst at KB Securities, as their new Chief Financial Officer (CFO). Mr. Kim began his career in the pharmaceutical and biotech investment sector at DB Securities. He has worked as an analyst for NH Securities, Hyundai Securities, Mirae Asset Securities, and KB Securities for 17 years. With the appointment of the new CFO, LISCure Biosciences plans to actively proceed with the listing process. They have signed an underwriting contract with Korea Investment & Securities and are currently undergoing due diligence. https://lnkd.in/gqrkcJFk
리스큐어바이오사이언시스, 신임 CFO에 김태희 KB증권 상무 영입
economist.co.kr
-
2023-09-25 Green Cross WellBeing Corp, LISCure Bio, and Microbiome Research Agreement Joint Research on Novel Individualized Formulation Ingredients On the 25th, Green Cross WellBeing Corp announced that it has signed a Memorandum of Understanding (MOU) with LISCure Bio Sciences and Microbiome-based on researching novel individualized formulation ingredients. Under the agreement, both companies will collaborate on researching new individualized materials based on microbiomes. They plan to conduct research and human application trials for these novel microbiomes, aiming to enhance differentiation and competitiveness within the individualized formulation ingredient market. https://lnkd.in/gnttgFGG
GC녹십자웰빙, 리스큐어바이오와 마이크로바이옴 연구 협약
hankyung.com